S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
CGC   14.22 (-7.24%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
T   39.63 (+0.33%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
BAC   32.96 (+0.09%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
CGC   14.22 (-7.24%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
T   39.63 (+0.33%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
BAC   32.96 (+0.09%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
CGC   14.22 (-7.24%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
T   39.63 (+0.33%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
BAC   32.96 (+0.09%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
CGC   14.22 (-7.24%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
T   39.63 (+0.33%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
BAC   32.96 (+0.09%)
DIS   147.65 (+2.06%)
Log in

Syndax Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:SNDX)

$6.78
-0.13 (-1.88 %)
(As of 11/18/2019 04:00 PM ET)
Today's Range
$6.64
Now: $6.78
$6.82
50-Day Range
$5.46
MA: $6.85
$7.78
52-Week Range
$3.39
Now: $6.78
$11.11
Volume8,114 shs
Average Volume114,199 shs
Market Capitalization$184.01 million
P/E RatioN/A
Dividend YieldN/A
Beta2.39
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNDX
CUSIPN/A
Phone781-419-1400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.52 million
Book Value$1.62 per share

Profitability

Net Income$-73,960,000.00
Net Margins-4,013.45%

Miscellaneous

Employees38
Market Cap$184.01 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive SNDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.


Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) issued its quarterly earnings data on Thursday, November, 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.07. The firm earned $0.38 million during the quarter, compared to the consensus estimate of $0.38 million. Syndax Pharmaceuticals had a negative net margin of 4,013.45% and a negative return on equity of 110.20%. View Syndax Pharmaceuticals' Earnings History.

When is Syndax Pharmaceuticals' next earnings date?

Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syndax Pharmaceuticals.

What price target have analysts set for SNDX?

7 analysts have issued 12 month price targets for Syndax Pharmaceuticals' stock. Their forecasts range from $5.00 to $19.00. On average, they expect Syndax Pharmaceuticals' stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 106.5% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals.

What is the consensus analysts' recommendation for Syndax Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals.

What are Wall Street analysts saying about Syndax Pharmaceuticals stock?

Here are some recent quotes from research analysts about Syndax Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States. " (10/12/2019)
  • 2. Nomura analysts commented, "Trial Design, Details, Market Opportunity, and Biology p.4-6. The Ph1/2 trial outline for SNDX-5613 (the clinical program is now called AUGMENT) was disclosed on the earnings call presentation; the IND was cleared on July 10 (note here). The Ph1 portion will not select pt for mutations (per FDA request), but will begin with BID doses at an estimated efficacious dose (based on preclinical data). Possible issues may arise with PK due to the need for continuous drug exposure; expected tox based on preclinical experiments has not been published but will be announced at an upcoming medical meeting (ASH?). Ph2 expansion will use a yet-to-be disclosed biomarker to assess PD. SNDX-6352 in cGVHD RP2D Data Delayed (Now 2H20E vs. 3Q19E); Pts Available." (8/11/2019)

Has Syndax Pharmaceuticals been receiving favorable news coverage?

News headlines about SNDX stock have been trending very negative on Monday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Syndax Pharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Syndax Pharmaceuticals.

Are investors shorting Syndax Pharmaceuticals?

Syndax Pharmaceuticals saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 756,500 shares, an increase of 8.0% from the September 15th total of 700,600 shares. Based on an average trading volume of 172,000 shares, the days-to-cover ratio is currently 4.4 days. Approximately 3.7% of the shares of the stock are sold short. View Syndax Pharmaceuticals' Current Options Chain.

Who are some of Syndax Pharmaceuticals' key competitors?

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include Opko Health (OPK), Exelixis (EXEL), TherapeuticsMD (TXMD), Idera Pharmaceuticals (IDRA), Verastem (VSTM), Cara Therapeutics (CARA), Proteostasis Therapeutics (PTI), Clearside Biomedical (CLSD), Micron Technology (MU) and Progenics Pharmaceuticals (PGNX).

Who are Syndax Pharmaceuticals' key executives?

Syndax Pharmaceuticals' management team includes the folowing people:
  • Dr. Briggs W. Morrison M.D., CEO & Director (Age 59)
  • Mr. Michael A. Metzger, Pres & COO (Age 48)
  • Mr. Richard P. Shea, CFO & Treasurer (Age 67)
  • Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 68)
  • Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 50)

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Who are Syndax Pharmaceuticals' major shareholders?

Syndax Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Ibex Investors LLC (0.05%). Company insiders that own Syndax Pharmaceuticals stock include Briggs Morrison, Michael L Meyers and Peter Ordentlich. View Institutional Ownership Trends for Syndax Pharmaceuticals.

Which institutional investors are buying Syndax Pharmaceuticals stock?

SNDX stock was bought by a variety of institutional investors in the last quarter, including Ibex Investors LLC. Company insiders that have bought Syndax Pharmaceuticals stock in the last two years include Briggs Morrison and Michael L Meyers. View Insider Buying and Selling for Syndax Pharmaceuticals.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Syndax Pharmaceuticals' stock price today?

One share of SNDX stock can currently be purchased for approximately $6.78.

How big of a company is Syndax Pharmaceuticals?

Syndax Pharmaceuticals has a market capitalization of $184.01 million and generates $1.52 million in revenue each year. The company earns $-73,960,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Syndax Pharmaceuticals employs 38 workers across the globe.View Additional Information About Syndax Pharmaceuticals.

What is Syndax Pharmaceuticals' official website?

The official website for Syndax Pharmaceuticals is http://www.syndax.com/.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]


MarketBeat Community Rating for Syndax Pharmaceuticals (NASDAQ SNDX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  267 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  535
MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Featured Article: Earnings Reports

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel